NKTR Nektar Therapeutics Stock Quote

NKTR [NASD]

Index	-	P/E	-	EPS (ttm)	-2.67	Insider Own	0.90%	Shs Outstand	185.85M	Perf Week	-13.96%
Market Cap	636.34M	Forward P/E	-	EPS next Y	-0.98	Insider Trans	-7.20%	Shs Float	184.15M	Perf Month	-28.18%
Income	-491.30M	PEG	-	EPS next Q	-0.91	Inst Own	95.50%	Short Float	9.96%	Perf Quarter	-65.34%
Sales	103.10M	P/S	6.17	EPS this Y	-14.80%	Inst Trans	1.30%	Short Ratio	4.34	Perf Half Y	-70.57%
Book/sh	3.27	P/B	1.04	EPS next Y	50.80%	ROA	-41.00%	Target Price	5.83	Perf Year	-80.71%
Cash/sh	3.55	P/C	0.95	EPS next 5Y	-7.30%	ROE	-65.60%	52W Range	3.52 - 19.37	Perf YTD	-74.91%
Dividend	-	P/FCF	-	EPS past 5Y	-21.00%	ROI	-65.70%	52W High	-82.50%	Beta	1.33
Dividend %	-	Quick Ratio	6.80	Sales past 5Y	-9.20%	Gross Margin	76.30%	52W Low	-3.69%	ATR	0.38
Employees	740	Current Ratio	7.00	Sales Q/Q	5.10%	Oper. Margin	-	RSI (14)	32.00	Volatility	8.10% 8.70%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	28.30%	Profit Margin	-	Rel Volume	0.76	Prev Close	3.57
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 05 AMC	Payout	-	Avg Volume	4.22M	Price	3.39
Recom	3.00	SMA20	-16.56%	SMA50	-30.19%	SMA200	-70.55%	Volume	3,209,996	Change	-5.04%

Apr-18-22

Downgrade

Goldman

Neutral → Sell

Mar-15-22

Downgrade

Mizuho

Buy → Neutral

$35 → $8

Mar-15-22

Downgrade

Cowen

Outperform → Market Perform

Mar-14-22

Downgrade

William Blair

Outperform → Mkt Perform

Mar-14-22

Downgrade

Stifel

Buy → Hold

$24 → $5

Mar-14-22

Downgrade

BTIG Research

Buy → Neutral

Mar-14-22

Downgrade

BofA Securities

Neutral → Underperform

$18 → $6

Mar-09-22

Upgrade

Oppenheimer

Perform → Outperform

$21

Nov-08-21

Upgrade

The Benchmark Company

Hold → Buy

$20

Sep-10-21

Initiated

BofA Securities

Neutral

$18

Jun-28-21

Upgrade

Stifel

Hold → Buy

$22 → $24

May-18-21

Resumed

Goldman

Neutral

$24

Feb-22-21

Downgrade

The Benchmark Company

Buy → Hold

Jan-06-21

Initiated

Stifel

Hold

$18

Sep-14-20

Initiated

JP Morgan

Neutral

$26

Jun-10-20

Downgrade

CFRA

Hold → Sell

May-12-20

Reiterated

H.C. Wainwright

Neutral

$32 → $26

Apr-22-20

Initiated

The Benchmark Company

Buy

$26

Mar-30-20

Upgrade

Goldman

Sell → Neutral

$18 → $20

Mar-04-20

Initiated

Barclays

Overweight

$30

May-16-22 02:09PM	Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans? Simply Wall St.
May-06-22 10:07AM	Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track Zacks
May-05-22 05:55PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates Zacks
May-04-22 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates Zacks
Apr-28-22 03:02PM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
Apr-27-22 12:00PM	Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store? Zacks
Apr-26-22 09:19AM	Nektar Therapeutics Will Cut 70% of Its Staff After Trial Failure Barrons.com -8.26%
08:53AM	Nektar to reduce workforce by 70% MarketWatch
Apr-25-22 06:00PM	Nektar to cut 500 jobs, sublease some Bay Area space after clinical trial failures American City Business Journals
05:57PM	Nektar to cut over 500 jobs following cancer drug failure Reuters
04:30PM	Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook PR Newswire
Apr-22-22 08:30AM	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan PR Newswire
Apr-20-22 12:54PM	Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More Zacks
09:17AM	Analysts Are Downgrading These 10 Pharmaceutical Stocks Insider Monkey
Apr-18-22 05:25PM	Billed as $3.6 billion deal to disrupt cancer, collaboration ends with thud American City Business Journals -23.05%
11:30AM	Why Nektar Therapeutics Stock Is Crashing Today Motley Fool
10:39AM	Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo MarketWatch
09:48AM	Nektar Therapeutics Stock Tanks on More Failed Trials of Its Cancer Drug Bempeg Barrons.com
09:32AM	Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures Zacks
Apr-14-22 04:42PM	Nektar stops clinical trials for key cancer drug, shares tumble Reuters
04:30PM	Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) PR Newswire
Apr-05-22 05:50AM	ProPhase Labs, Inc. (PRPH) Soars 11.2%: Is Further Upside Left in the Stock? Zacks
Mar-30-22 11:30AM	Why Is Nektar (NKTR) Down 47.6% Since Last Earnings Report? Zacks
Mar-16-22 12:32PM	Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More Zacks
Mar-15-22 10:38AM	Nektar (NKTR) Plunges on Bempeg's Melanoma Study Failure Zacks +7.69%
Mar-14-22 05:43PM	Longtime biotech plots 'substantial' changes after cancer drug failure American City Business Journals -60.87%
04:27PM	Nektar Therapeutics Loses 60% Its Value As Bristol Myers-Paired Melanoma Test Flops Investor's Business Daily
12:01PM	Why Nektar Therapeutics Stock Is Imploding Today Motley Fool
08:20AM	Nektar Therapeutics (NASDAQ:NKTR) investors are sitting on a loss of 70% if they invested three years ago Simply Wall St.
07:40AM	Nektar's stock falls 44% after experimental therapy fails to work in melanoma patients MarketWatch
07:05AM	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial PR Newswire
06:59AM	Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma Business Wire
Mar-04-22 09:22AM	Are Options Traders Betting on a Big Move in Nektar Therapeutics (NKTR) Stock? Zacks
Mar-01-22 10:43AM	Billionaire Stanley Druckenmiller Just Dumped These 10 Stocks Insider Monkey +7.23%
09:55AM	Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022 Zacks
Feb-28-22 05:35PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results PR Newswire
Feb-17-22 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets PR Newswire
03:02PM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-08-22 09:38AM	Grandfield & Dodd, Llc Buys AutoZone Inc, Teledyne Technologies Inc, IAC/InterActiveCorp, ... GuruFocus.com
Feb-03-22 01:38PM	Northwestern Mutual Investment Management Company, Buys iShares iBoxx USD Investment Grade ... GuruFocus.com -5.52%
Jan-31-22 03:35PM	Biotech startup picked up rebounded CEO. Here's why they think it's a good match. American City Business Journals
Jan-21-22 01:38PM	Founders Capital Management Buys iShares TIPS Bond ETF, AT&T Inc, Vanguard Health Care ETF, ... GuruFocus.com -7.05%
Jan-20-22 09:38PM	Retirement Systems of Alabama Buys Applied Materials Inc, Broadcom Inc, Johnson & Johnson, ... GuruFocus.com
Jan-19-22 01:38PM	New Mexico Educational Retirement Board Buys Alcoa Corp, EPAM Systems Inc, Bruker Corp, Sells ... GuruFocus.com
Jan-05-22 09:00AM	Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference PR Newswire -6.92%
Jan-03-22 09:38PM	Private Asset Management Inc Buys ASML Holding NV, Public Storage, Palantir Technologies Inc, ... GuruFocus.com
Dec-31-21 08:56AM	Is the Options Market Predicting a Spike in Nektar Therapeutics (NKTR) Stock? Zacks
Dec-15-21 09:10AM	Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis PR Newswire
Dec-14-21 11:31AM	Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2022 Simply Wall St.
Dec-13-21 03:59PM	Should I Buy Nektar Therapeutics (NKTR)? Insider Monkey
09:00AM	Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting PR Newswire
Dec-11-21 12:38AM	Horizon Kinetics Buys Tejon Ranch Co, Madison Square Garden Entertainment Corp, Alerian MLP ... GuruFocus.com
Dec-03-21 07:51PM	Signature Bank, SolarEdge Technologies and FactSet Research Systems Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire -5.08%
Nov-30-21 08:00AM	Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting PR Newswire
Nov-19-21 11:52AM	Nektar Therapeutics Insider Trades $315K In Company Stock Benzinga
08:20AM	We're Interested To See How Nektar Therapeutics (NASDAQ:NKTR) Uses Its Cash Hoard To Grow Simply Wall St.
Nov-15-21 08:30AM	Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D. PR Newswire
Nov-12-21 07:00AM	Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
Nov-09-21 08:15AM	Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting PR Newswire -5.67%
Nov-05-21 04:11PM	Why Nektar Therapeutics Stock Plunged Today Motley Fool -19.22%
11:00AM	Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track Zacks
Nov-04-21 10:32PM	Nektar Therapeutics (NKTR) Q3 2021 Earnings Call Transcript Motley Fool
05:35PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Third Quarter 2021 Financial Results PR Newswire
Oct-26-21 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets PR Newswire
Oct-25-21 04:01PM	Hedge Funds Are Buying Nektar Therapeutics (NKTR) Insider Monkey
Sep-22-21 11:09AM	Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255 Zacks
Sep-21-21 11:02AM	Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study Benzinga +8.45%
09:00AM	Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study PR Newswire
Sep-13-21 11:47AM	Director Of Nektar Therapeutics Trades $544.92 Thousand In Company Stock Benzinga
Sep-02-21 12:03PM	Even after rising 9.3% this past week, Nektar Therapeutics (NASDAQ:NKTR) shareholders are still down 77% over the past three years Simply Wall St.
Aug-06-21 12:31PM	Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track Zacks
Aug-05-21 09:31PM	Nektar Therapeutics (NKTR) Q2 2021 Earnings Call Transcript Motley Fool
05:45PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports Second Quarter 2021 Financial Results PR Newswire
Jul-29-21 03:05PM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Jul-27-21 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets PR Newswire
Jul-26-21 05:09PM	Were Hedge Funds Right About Nektar Therapeutics (NKTR)? Insider Monkey
Jul-19-21 09:00AM	Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer PR Newswire
Jun-07-21 08:30AM	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference PR Newswire
Jun-04-21 10:46AM	Should Shareholders Reconsider Nektar Therapeutics' (NASDAQ:NKTR) CEO Compensation Package? Simply Wall St.
May-27-21 06:36AM	We're Interested To See How Nektar Therapeutics (NASDAQ:NKTR) Uses Its Cash Hoard To Grow Simply Wall St.
May-20-21 11:00AM	Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity PR Newswire
May-18-21 08:00AM	Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) PR Newswire
May-10-21 03:09AM	Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last? Zacks
May-07-21 03:30AM	Nektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript Motley Fool +8.53%
May-06-21 05:45PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:15PM	Nektar Therapeutics Reports First Quarter 2021 Financial Results PR Newswire
Apr-29-21 12:34PM	Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline Zacks
Apr-27-21 06:00PM	Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets PR Newswire
Mar-27-21 11:31AM	Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound? Zacks
Feb-26-21 09:09AM	Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track Zacks
07:20AM	Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2021 Simply Wall St.
03:11AM	Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues SmarterAnalyst
01:01AM	Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript Motley Fool
Feb-25-21 05:10PM	Nektar Therapeutics: Q4 Earnings Insights Benzinga
03:15PM	Nektar Therapeutics to Host Earnings Call ACCESSWIRE
Feb-18-21 05:30PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets PR Newswire
Feb-17-21 04:19PM	Nektar Therapeutics Breaks Out On Combo Study With Merck's Keytruda Investor's Business Daily +13.36%

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	May 16	Sale	3.95	21,673	85,608	276,399	May 17 09:40 PM
Wilson Mark Andrew	SVP & General Counsel	May 16	Sale	3.95	3,136	12,387	117,939	May 17 09:38 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	May 16	Sale	3.95	5,841	23,072	170,427	May 17 09:36 PM
ROBIN HOWARD W	President & CEO	May 16	Sale	3.95	36,529	144,290	620,941	May 17 09:35 PM
NORTHCOTT JOHN	SVP & Chief Commercial Officer	May 16	Sale	3.95	4,592	18,138	223,210	May 17 09:33 PM
Labrucherie Gil M	SVP, COO & CFO	May 16	Sale	3.95	17,448	68,920	312,905	May 17 09:32 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 16	Sale	10.95	10,912	119,486	274,122	Feb 18 06:20 PM
Wilson Mark Andrew	SVP & General Counsel	Feb 16	Sale	10.95	3,661	40,088	121,075	Feb 18 06:18 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Feb 16	Sale	10.95	2,363	25,875	165,318	Feb 18 06:18 PM
ROBIN HOWARD W	President & CEO	Feb 16	Sale	10.95	12,480	136,656	589,020	Feb 18 06:16 PM
NORTHCOTT JOHN	SVP & Chief Commercial Officer	Feb 16	Sale	10.95	4,852	53,129	227,802	Feb 18 06:15 PM
Labrucherie Gil M	SVP, COO & CFO	Feb 16	Sale	10.95	7,579	82,990	301,603	Feb 18 06:14 PM
Labrucherie Gil M	SVP, COO & CFO	Nov 18	Sale	12.69	3,000	38,070	256,682	Nov 18 06:06 PM
Labrucherie Gil M	SVP, COO & CFO	Nov 16	Sale	13.16	21,149	278,321	259,682	Nov 18 06:06 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 16	Sale	13.16	20,869	274,636	232,084	Nov 17 06:11 PM
Wilson Mark Andrew	SVP & General Counsel	Nov 16	Sale	13.16	6,564	86,382	86,436	Nov 17 06:09 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Nov 16	Sale	13.16	6,741	88,712	145,981	Nov 17 06:08 PM
NORTHCOTT JOHN	SVP & Chief Commercial Officer	Nov 16	Sale	13.16	6,061	79,763	194,854	Nov 17 06:06 PM
ROBIN HOWARD W	President & CEO	Nov 16	Sale	13.16	42,773	562,893	475,450	Nov 17 06:07 PM
GREER R SCOTT	Director	Nov 09	Option Exercise	12.80	12,500	160,000	293,374	Nov 09 05:05 PM
Curet Myriam	Director	Sep 22	Sale	17.78	3,665	65,164	25,775	Sep 24 06:14 PM
CHESS ROBERT	Director	Sep 22	Sale	17.94	4,600	82,524	279,873	Sep 24 06:13 PM
Ajer Jeffrey Robert	Director	Sep 22	Sale	17.78	3,665	65,164	32,510	Sep 24 06:12 PM
WHITFIELD ROY A	Director	Sep 16	Option Exercise	13.80	40,000	552,000	225,850	Sep 17 06:44 PM
CHESS ROBERT	Director	Sep 09	Option Exercise	13.80	10,279	141,850	284,552	Sep 10 06:03 PM
CHESS ROBERT	Director	Sep 09	Sale	16.02	10,279	164,670	274,273	Sep 10 06:03 PM
CHESS ROBERT	Director	Sep 08	Option Exercise	13.80	8,000	110,400	282,273	Sep 10 06:03 PM
CHESS ROBERT	Director	Sep 08	Sale	16.00	8,000	128,000	274,273	Sep 10 06:03 PM
GREER R SCOTT	Director	Aug 31	Option Exercise	12.70	45,000	571,500	270,674	Aug 31 06:26 PM
Labrucherie Gil M	SVP, COO & CFO	Aug 17	Sale	13.56	3,000	40,680	240,231	Aug 18 06:58 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 16	Sale	13.83	7,662	105,965	212,803	Aug 18 07:04 PM
Wilson Mark Andrew	SVP & General Counsel	Aug 16	Sale	13.83	1,910	26,415	72,900	Aug 18 07:02 PM
Thomsen Jillian B.	SVP & Chief Accounting Officer	Aug 16	Sale	13.83	13,339	184,478	137,822	Aug 18 07:00 PM
ROBIN HOWARD W	President & CEO	Aug 16	Sale	13.83	11,515	159,252	424,123	Aug 18 07:01 PM
NORTHCOTT JOHN	SVP & Chief Commercial Officer	Aug 16	Sale	13.83	6,192	85,635	200,915	Aug 18 06:59 PM
Labrucherie Gil M	SVP, COO & CFO	Aug 16	Sale	13.83	7,867	108,801	243,231	Aug 18 06:58 PM
CHESS ROBERT	Director	Jul 22	Option Exercise	13.80	91	1,256	280,664	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 22	Sale	16.80	91	1,529	280,573	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 21	Option Exercise	13.80	3,524	48,631	284,097	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 21	Sale	16.81	3,524	59,238	280,573	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 20	Option Exercise	13.80	2,106	29,063	282,679	Jul 22 07:13 PM
CHESS ROBERT	Director	Jul 20	Sale	16.80	2,106	35,381	280,573	Jul 22 07:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience